Table 3.
BRCA pathway aberrations and clinicopathological features.
| Features | BRCA pathway genes | P | BRCA2 expression | P | ||
|---|---|---|---|---|---|---|
| Potentially deleterious mutations* | Wild type or benign mutations** | Retain | Reduced | |||
| BRCA2 mutation | ||||||
| Mutant | 8 | 2 | — | 8 | 2 | 1.00 |
| Wild | 1 | 31 | — | 27 | 5 | |
| Age at operation | ||||||
| Mean (range) | 68 (53–79) | 65 (43–87) | 0.40 | 65 (43–87) | 70 (56–77) | 0.23 |
| T*** | ||||||
| T1, T2 | 3 | 9 | 0.70 | 10 | 2 | 1.00 |
| T3, T4 | 6 | 24 | 25 | 5 | ||
| N*** | ||||||
| N0 | 1 | 12 | 0.23 | 11 | 2 | 1.00 |
| N1, N2 | 8 | 21 | 24 | 5 | ||
| Stage*** | ||||||
| 0 | 0 | 0 | 0.44 | 0 | 0 | 0.52 |
| I | 0 | 1 | 1 | 0 | ||
| II | 0 | 6 | 5 | 1 | ||
| III | 6 | 12 | 13 | 5 | ||
| IVa | 3 | 13 | 15 | 1 | ||
| IVb | 0 | 1 | 1 | 0 | ||
| Histology | 0 | 0 | 0.44 | |||
| Tubular adenocarcinoma | 8 | 27 | 1.00 | 30 | 5 | 0.58 |
| other | 1 | 6 | 5 | 2 | ||
| Recurrence | ||||||
| Yes | 4 | 23 | 0.24 | 23 | 4 | 0.69 |
| No | 5 | 10 | 12 | 3 | ||
| Previous cancer history | ||||||
| Yes | 1 | 10 | 0.40 | 10 | 1 | 0.65 |
| No | 8 | 23 | 25 | 6 | ||
| Family history of any cancers | ||||||
| Yes | 3 | 18 | 0.45 | 17 | 4 | 1.00 |
| No | 6 | 15 | 18 | 3 | ||
| Family history of pancreatic cancer | ||||||
| Yes | 0 | 5 | 0.57 | 4 | 1 | 1.00 |
| No | 9 | 28 | 31 | 6 | ||
| Prognosis | ||||||
| 5-year overall survival | 68.6% | 19.2% | 0.031 | 34.3% | 0% | 0.83 |
*Patients with mutations predicted as pathogenic, conflicting, uncertain, or no information by ClinVar. **Patients with mutations predicted as benign by Clinvar or those without mutations. ***According to Japan Pancreas Society Classification (6th ed.).